Drug Trial Radar · NCT04058366
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
Last checked: Nov 19, 2026Latest source record: Jan 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Dec 5, 2019
Primary completion
Dec 16, 2022
Study completion Dec 16, 2022
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Aug 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).
Conditions
- Cystic Fibrosis
Interventions
ELX/TEZ/IVADrug
Fixed-dose combination (FDC) tablet for oral administration.
IVADrug
Tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Baseline up to Week 100
Locations
84 sites in 12 countries. Site status is shown where the registry gives one.
Banner University of Arizona Medical Center
Tucson, Arizona
Miller Children's Hospital / Long Beach Memorial
Long Beach, California
Stanford University
Palo Alto, California
University of California Davis Medical Center
Sacramento, California
University of California San Francisco, Lung Transplant Program
San Francisco, California
National Jewish Health
Denver, Colorado
University of Miami Miller School of Medicine
Miami, Florida
Central Florida Pulmonary Group, PA
Orlando, Florida
Indiana University
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center
Boston, Massachusetts
Boston Children's Hospital
Boston, Massachusetts
Michigan Medicine
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine / St. Louis Children's Hospital
St Louis, Missouri
Mount Sinai Beth Israel
New York, New York
Columbia University Medical Center
New York, New York
University of North Carolina Hospitals
Chapel Hill, North Carolina
UC Health Holmes
Cincinnati, Ohio
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center
Toledo, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Dell Children's Medical Group
Austin, Texas
The University of Texas Southwestern Medical Center
Dallas, Texas
Texas Children's Hospital
Houston, Texas
University of Utah / Primary Children's Medical Center
Salt Lake City, Utah
University of Washington Medical Center
Seattle, Washington
University of Wisconsin Hospital and Clinics
Madison, Wisconsin
The Prince Charles Hospital
Chermside, Australia
Alfred Hospital
Melbourne, Australia
Telethon Kids Institute
Nedlands, Australia
The Royal Children's Hospital
Parkville, Australia
Mater Adult Hospital
South Brisbane, Australia
Queensland Children's Hospital
South Brisbane, Australia
Westmead Hospital
Westmead, Australia
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.